# Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

> **NCT03202303** · PHASE2 · RECRUITING · sponsor: **Montefiore Medical Center** · enrollment: 100 (estimated)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** Cannabidivarin
- **DRUG:** Matched Placebo

## Key facts

- **NCT ID:** NCT03202303
- **Lead sponsor:** Montefiore Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-04-12
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-10-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03202303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03202303, "Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03202303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*